Primary Focal Segmental Glomerulosclerosis
Article Sidebar
Main Article Content
Abstract
Primary focal segmental glomerulosclerosis (FSGS) has become increasing prevalent in the recent years, and it is one of the important causes of chronic kidney disease. The presentation may range from asymptomatic proteinuria to full-blown nephrotic syndrome. To make a correct diagnosis, kidney biopsy is mandatory. An autoimmune process is believed to be involved in the pathogenesis of primary FSGS, but the mechanisms remain poorly understood. The treatment includes symptomatic management to reduce proteinuria and blood pressure and immunosuppressive therapy. Glucocorticoid is the first line treatment with calcineurin inhibitor as an alternative therapy. The goal is to reduce proteinuria, lower blood pressure and preserve kidney function.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under CC BY-NC-ND 4.0 license, which allows for non-commercial reuse of the published paper as long as the published paper is fully attributed. Anyone can share (copy and redistribute) the material in any medium or format without having to ask permission from the author or the Nephrology Society of Thailand.
References
Paisal P, Ratana C, Chairat S, Boonyarit C, Somkiat V, Kriengsak V, et al. An analysis of 3,555 cases of renal biopsy in Thailand. J Med Assoc Thai. 2006;89:106-11.
Chagriya K, Jeffrey K, Paul E. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23(2):172-82.
Vivette D, D’Agati, Frederick J. K, Ronald J. F. Focal segmental glomerulosclerosis. N Eng J Med. 2011;365: 2398-411.
Luca P, Sara C, Ariela B, Giuseppe R. Podocyte-actin dynamics in health and disease. Nat Rev Nephrol. 2016;12(11):692-710.
Gerald B. Appel, Vivette D. D’Agati. Primary and secondary causes of focal and segmental glomerulosclerosis. In: John F, Jurgen F, Marcello T, Richard J. Comphrehensive clinical nephrology. 6 ed.Philadelphia: Elsevier; 2019.
KDIGO 2021 clinical practice guideline for the management of glomerular disease. Kidney Int. 2021;100(4S):S1-S276
Manuel A. P, Claudio P. Autoimmunity in focal segmental glomerulosclerosis: A long-standing yet elusive association. Front Med. 2020;7:604961.
Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, et al. Renal and hematological effects of CLCF-1, a B-cell stimulating cytokine of the IL-6 family. J Immunol Res. 2015;714964.
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17:952-60.
Delvelle M, Sigdel TK, Wei C, Li J, Hsieh S-C, Fornoni A, et al. A circulating antibody panel for transplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6:256ra136.
Natalia P, Conxita J, Joana S, Lluis G, Francisco G. R, Carlos J, et al. Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-center cohort study. Transpl Int . 2019;32(3):313-22.
Man-Hoon H, Yong-Jin K. Practical application of Columbia classification for focal segmental glomerulosclerosis. Biomed Res Int. 2016;9375753.
Shabaka A, Ana T. R, Geme F. Focal segmental glomerulosclerosis: State-of-the-art and clinical perspective. Nephron. 2020;144(9):413-27.
Stephen M. K, Rush P. Treatment of primary focal segmental glomerulosclerosis. J Am Soc Nephrol. 2012;23(11)1769-76.
Jame J. R, Stephen M. K, Schwartz M. Focal segmental glomerulosclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995;25(4):534-42.
Stephen T, Catherine A. W, Judith A. M, James W. S, Daniel C. C. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16:1061-8.
Goumenos D.S., Tsagalis G, Nahas A, John S, Periklis D, John V, et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: A five-year follow-up study. Nephron Clin Pract. 2006;104:c75–82.
Claudio P, Margarita V, Banfi G, Cesana B, Pozzi C, Pani A, et al. Can prolong treatment improve the prognosis in adults with focal segmental glomerulosclerosis. Am J Kidney Dis. 1999;34(4):618-25.
Shouichi F, Yoshitaka Y, Hisanaga S, Morita S, Eto T, Tanaka K. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy andfrequency of relapse. Am J Kidney Dis. 1991;17(6):687-92.
Neill D, Ajay D, Jane O, Thomas C, Megan G, Adam M, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004;25(8):2537-41.
Claudio P, Gianfranco R, Edenfonti A, Altieri P, Rivolta E, Rinaldi S, et al. A Randomized trial of cyclosporine in steroid resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43(6):1377-84.
Daniel C, Gerald B, Hebert L, Hunsicker L, Pohl M, Hoy W, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int. 1999;56(6):2220-6.